In­cyte is 'op­ti­mistic' about skin dis­ease drug Opzelu­ra as pre­scrip­tions grow 77% in Q4

In­cyte ex­pects its atopic der­mati­tis and vi­tili­go treat­ment Opzelu­ra to be a “key con­trib­u­tor” to growth in 2024 af­ter sales jumped 78% in the fourth quar­ter.

Opzelu­ra brought in $109.2 mil­lion in the last three months of the year, with the in­crease dri­ven large­ly by new pa­tients, ex­pand­ed pay­er cov­er­age and pre­scrip­tion re­fills in both in­di­ca­tions.

“We re­main very op­ti­mistic about the long-term po­ten­tial of Opzelu­ra as we con­tin­ue to see strong up­take,” Bar­ry Flan­nel­ly, In­cyte’s ex­ec­u­tive VP and gen­er­al man­ag­er of North Amer­i­ca, said dur­ing Tues­day’s earn­ings call, de­scrib­ing it as “one of the best re­cent der­ma­tol­ogy launch­es.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER